☆ 4.7 Article

In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Chemistry, Multidisciplinary

Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy

Yucheng Xiang et al.

Summary: ER-targeted delivery of doxorubicin (DOX) attenuates its original cytotoxic effect while increasing the ability to induce immunogenic cell death; High ER-targeting efficiency correlates with greater ER stress, leading to a shift in the mode of action of DOX from nuclear DNA damage to ER stress-mediated effects; Combining naive and ER-targeted DOX for in vivo application results in tumor regression through a dual mechanism of direct killing and ICD-associated immunity, enhanced by simultaneous inhibition of adaptive PD-L1 enrichment.

SMALL (2022)

Add to Collection

Article Neurosciences

Connexin30-Deficiency Causes Mild Hearing Loss With the Reduction of Endocochlear Potential and ATP Release

Junmin Chen et al.

Summary: This study established a new Cx30 knockout mouse model using CRISPR/Cas9 technology, and found that the lack of Cx30 can cause mild hearing loss with approximately 30% reduction of Cx26. This suggests that Cx30 may play an important role in hearing development.

FRONTIERS IN CELLULAR NEUROSCIENCE (2022)

Add to Collection

Article Pharmacology & Pharmacy

Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice

Rongjie Zhang et al.

Summary: Sodium tanshinone IIA sulfonate (STS) acts as an immunotherapy agent by inhibiting both IDO1 and TDO2 in colorectal cancer (CRC).

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1

Eun-Ji Choe et al.

Summary: Clinical studies have demonstrated that statins can improve the efficacy of PD-1/PD-L1 blockade therapy for breast cancer. This study reveals that atorvastatin (ATO) enhances the efficacy of anti-PD-L1 therapy by reducing PD-L1 expression in extracellular vesicles (EVs) and inhibiting EV secretion in breast cancer cells. ATO regulates the Rab proteins involved in EV biogenesis and secretion, leading to reduced EV secretion. In addition, ATO downregulates PD-L1 expression through the Ras-activated MAPK signaling pathway. Moreover, ATO promotes antitumor efficacy by inducing T cell-mediated tumor destruction when combined with an anti-PD-L1 antibody.

PHARMACEUTICS (2022)

Add to Collection

Review Oncology

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Qing Wu et al.

Summary: The US FDA has been at the forefront of drug evaluation and supervision. Over the past 31 years, 1050 drugs have been approved, with 228 of them being cancer therapeutics or cancer-related drugs. These drugs have evolved from broad-spectrum antitumor small molecules to more precise monoclonal antibodies and antibody-drug conjugates. However, the development of antitumor drugs is still limited by the available targets, mainly receptor tyrosine kinases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Review Immunology

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Zefan Liu et al.

Summary: This review systematically summarizes the recent applications of nanotechnology in colorectal cancer immunotherapy, including targeting immune checkpoint inhibitors, increasing tumor immunogenicity, remodeling tumor microenvironment, and pre-sensitizing immune systems. The advantages of nanotechnology in innovating the mode-of-actions of immune checkpoint blockade, modulating intestinal microbiome, and integrating the whole process of antigen presentation are highlighted in this review.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs

Qian Wang et al.

Summary: Cholesterol is crucial for the development and survival of cancer cells. Previous studies have shown that cholesterol-lowering drugs can inhibit the high expression of PD-L1, which contributes to immunoevasion in cancer cells. However, the mechanism of how cholesterol regulates the stability of PD-L1 is still unclear. This study demonstrates that cholesterol can directly bind to PD-L1 through specific amino acid motifs, forming a sandwich-like structure and stabilizing PD-L1 to prevent degradation. These findings reveal a unique regulatory mechanism and provide a potential strategy to overcome PD-L1-mediated immunoevasion in cancer.

SCIENCE ADVANCES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Small-Molecule PROTACs for Cancer Immunotherapy

Zefan Liu et al.

Summary: Small-molecule compounds can effectively solve the problems of poor physicochemical properties in macromolecular drugs, improving their application in tumor immunotherapy. The proteolysis targeting chimera (PROTAC) technology provides a novel mode of action for small molecules to interact with therapeutic targets, particularly proteins. This review comprehensively summarizes the immunological targets that have been studied and those that are yet to be explored for PROTAC technology, aiming to provide more options and opportunities for small-molecule-based tumor immunotherapy. In addition, it discusses novel directions to enhance and broaden the efficiency of protein degradation in PROTAC design.

MOLECULES (2022)

Add to Collection

Review Chemistry, Multidisciplinary

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Qian Wu et al.

Summary: PD-1/PD-L1 signaling pathway is a target for anticancer drugs, and the development of small molecule inhibitors provides a new avenue for tumor immunotherapy.

ACTA PHARMACOLOGICA SINICA (2021)

Add to Collection

Review Engineering, Biomedical

Recent Advances in Injectable Hydrogels for Controlled and Local Drug Delivery

Fabio Rizzo et al.

Summary: Injectable hydrogels are of great interest in the biomedical field for their potential in controlled and localized drug delivery while limiting nonspecific drug distribution in healthy tissues. Stimuli-responsive injectable hydrogels have been designed to change shape or volume in response to environmental stimuli, ensuring optimal drug delivery to target sites.

ADVANCED HEALTHCARE MATERIALS (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Tumor-specific fluorescence activation of rhodamine isothiocyanate derivatives

Shiqi Hu et al.

Summary: Research shows that rhodamine B isothiocyanate derivatives (RBITCs) exhibit unique tumor-specific fluorescence, which can be utilized for cancer imaging and early diagnosis.

JOURNAL OF CONTROLLED RELEASE (2021)

Add to Collection

Article Multidisciplinary Sciences

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1

Jang-June Park et al.

Summary: A mechanism of inhibiting programmed death-ligand 1 through small molecule-induced dimerization and internalization was reported, showing potential therapeutic implications in oncology and chronic viral infections.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Oncology

Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma

Stephen C. Frederico et al.

Summary: The use of immunotherapies for brain tumors has generated excitement, but challenges remain in treating GBM due to its immunologically cold nature. Strategies such as vaccine therapy combined with immune checkpoint inhibitors are being explored to overcome these challenges and enhance treatment options for patients with GBM in the future.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

Gi-Hoon Nam et al.

Summary: The study shows that statins can enhance the immunogenicity of KRAS-mutant tumors by inducing immunogenic cell death and enhancing the cross-priming ability of dendritic cells, thereby stimulating CD8+ T-cell immune responses against the tumors. Combination therapy using statins and other agents can significantly increase the immunogenicity of KRAS(mut) tumors and improve tumor-specific immunity, overcoming resistance to PD-1 blockade therapies and increasing survival rates in KRAS(mut) tumor models.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Cell Biology

Statins Decrease Programmed Death-Ligand 1 (PD-L1) by Inhibiting AKT and β-Catenin Signaling

Woo-Jin Lim et al.

Summary: Studies have shown that statins can reduce PD-L1 expression in cancer cells by inhibiting the AKT and beta-catenin signaling pathways, providing compelling evidence for the clinical evaluation of combining statins with immune checkpoint inhibitors for cancer therapy.

CELLS (2021)

Add to Collection

Review Immunology

Tumor-infiltrating lymphocytes in the immunotherapy era

Sterre T. Paijens et al.

Summary: The success of cancer immune checkpoint blockade has led to increased interest in tumor-infiltrating lymphocytes (TILs) across different cancer types. Single-cell analysis has revealed high cellular heterogeneity in TILs, with distinct patterns of immune activation and exhaustion. While TIL distributions are similar across tumor types, their responses to immunotherapy vary, highlighting the complexity of tumor-immune interactions.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Article Nanoscience & Nanotechnology

Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer

Yucheng Xiang et al.

ACS APPLIED MATERIALS & INTERFACES (2020)

Add to Collection

Article Chemistry, Analytical

Polypeptide-rhodamine B probes containing laminin/fibronectin receptor-targeting sequence (YIGSR/RGD) for fluorescent imaging in cancers

Fan Liu et al.

TALANTA (2020)

Add to Collection

Review Oncology

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Lorenzo Galluzzi et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection

Article Chemistry, Physical

Structural and therapeutic properties of curcumin solubilized pluronic F127 micellar solutions and hydrogels

R. Ganguly et al.

JOURNAL OF MOLECULAR LIQUIDS (2020)

Add to Collection

Article Oncology

Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer

Cheng Chen et al.

ONCOLOGY REPORTS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Recent advances in drug delivery systems for enhancing drug penetration into tumors

Bin He et al.

DRUG DELIVERY (2020)

Add to Collection

Review Immunology

Tumour-intrinsic resistance to immune checkpoint blockade

Anusha Kalbasi et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Review Chemistry, Medicinal

Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment

Chunlin Zhuang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)

Add to Collection

Article Chemistry, Multidisciplinary

Injectable thermosensitive hydrogel systems based on functional PEG/PCL block polymer for local drug delivery

Hongzhang Deng et al.

JOURNAL OF CONTROLLED RELEASE (2019)

Add to Collection

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Immune Checkpoint Inhibitors: Basics and Challenges

Bin Li et al.

CURRENT MEDICINAL CHEMISTRY (2019)

Add to Collection

Review Oncology

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

Arsen Osipov et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Degradable and Injectable Hydrogel for Drug Delivery in Soft Tissues

Vincent Pertici et al.

BIOMACROMOLECULES (2019)

Add to Collection

Review Pharmacology & Pharmacy

In situ forming injectable hydrogels for drug delivery and wound repair

Robert Dimatteo et al.

ADVANCED DRUG DELIVERY REVIEWS (2018)

Add to Collection

Review Oncology

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways

Pottayil G. Sasikumar et al.

BIODRUGS (2018)

Add to Collection

Article Chemistry, Multidisciplinary

Enhancing Antitumor Efficacy by Simultaneous ATP-Responsive Chemodrug Release and Cancer Cell Sensitization Based on a Smart Nanoagent

Xiao-Rong Song et al.

ADVANCED SCIENCE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Immune checkpoint inhibitors: recent progress and potential biomarkers

Pramod Darvin et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2018)

Add to Collection

Review Oncology

Hallmarks of response to immune checkpoint blockade

Alexandria P. Cogdill et al.

BRITISH JOURNAL OF CANCER (2017)

Add to Collection

Review Pharmacology & Pharmacy

Injectable hydrogel-based drug delivery systems for local cancer therapy

Mohammad Norouzi et al.

DRUG DISCOVERY TODAY (2016)

Add to Collection

Review Nanoscience & Nanotechnology

Designing hydrogels for controlled drug delivery

Jianyu Li et al.

NATURE REVIEWS MATERIALS (2016)

Add to Collection

Review Oncology

Clinical significance of tumor-infiltrating lymphocytes in breast cancer

Sasha E. Stanton et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)

Add to Collection

Review Oncology

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Suzanne L. Topalian et al.

NATURE REVIEWS CANCER (2016)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology

INFLAMMATORY DISEASES Hydrogel drug delivery for inflammatory bowel disease

Megan Cully

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection

Article Oncology

Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer

P. Balermpas et al.

BRITISH JOURNAL OF CANCER (2014)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology

The immune checkpoint inhibitors: where are we now?

Rachel Webster

NATURE REVIEWS DRUG DISCOVERY (2014)

Add to Collection

Review Medicine, General & Internal

HMG CoA reductase inhibitors (statins) for dialysis patients

Suetonia C. Palmer et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)

Add to Collection

Review Medicine, General & Internal

Statins for the primary prevention of cardiovascular disease

Fiona Taylor et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)

Add to Collection

Article Engineering, Biomedical

The biocompatibility of Pluronic (R) F127 fibrinogen-based hydrogels

Yonatan Shachaf et al.

BIOMATERIALS (2010)

Add to Collection

Editorial Material Chemistry, Multidisciplinary

Impact of Nanotechnology on Drug Delivery

Omid C. Farokhzad et al.

ACS NANO (2009)

Add to Collection

Review Polymer Science

Hydrogels in drug delivery: Progress and challenges

Todd R. Hoare et al.

POLYMER (2008)

Add to Collection

Article Chemistry, Multidisciplinary

Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration:: In vitro and in vivo characterization

Yu Liu et al.

JOURNAL OF CONTROLLED RELEASE (2007)

Add to Collection

Review Oncology

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

WWL Wong et al.

LEUKEMIA (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.